Latest news

Scientific events

Rencontre et débat


[De l'eau dans le gaz] Une nouvelle thérapie pour soulager l'arthrose avec Garance Saint-Pe et Léa Terriac

Léa Terriac et Garance Saint Pe sont doctorantes au laboratoire RMeS de Nantes (Nantes Université). Leur recherche se concentre sur l'élaboration de nouveaux traitements destinés à soulager les douleurs de l'arthrose en utilisant un hydrogel. Nous explorerons leur travail sur le développement de ces traitements et dans la mise au point des techniques d'administration associées.

L'arthrose est une maladie invalidante qui touche une part considérable de la population. Ensemble, nous plongerons dans les mécanismes de cette pathologie et découvrirons les espoirs que suscitent ces nouvelles thérapies.

Rendez-vous le 22 mai à 15h00 sur la chaine Twitch d'EchoSciences Pays de la Loire  twitch.tv/echosciencespdl


 

Colloque «  Utilisation des vésicules extra-cellulaires en clinique - Approche biomarqueurs et stratégies thérapeutiques » le 11/06/2024  

Le réseau G0-EV " Grand-Ouest Extracellular Vesicle Network ", crée en 2018, fédère les scientifiques d'une 20ène de laboratoires multi-sites (Nantes-Angers-Rennes) et le réseau des plateformes Biogenouest.

L'objectif de l'organisation de ce congrès est de faire le point sur les innovations technologiques et les perspectives thérapeutiques autour de la thématique des EV en intégrant les plateformes technologiques et les cliniciens dans la dynamique des chercheurs ligériens.

Lien vers le site

Scientifique et Organisation

Sophie Brouard, DR CNRS, CRT2I
Pierre-François Cartron, CR ICO, CRCI2NA
Delphine Fradin, CR INSERM, CRCI2NA
Angélique Galvani, MCU, Nantes Univ, RMeS
Laetitia Guével, MCU, Nantes Univ, CRCI2NA ; responsable scientifique
Amandine Dupuy, pHD student, Nantes Univ, CRT2I Rosalie Moreau, AI, INSERM, CRCI2NA
Mehdi Tazi, Coordinateur du réseau GO-EV

 

Colloque «  Fabrication additive et interdisciplinarité pour l’industrie et la santé du futur » le 11/06/2024  
 

Le colloque vise d’une part à mettre en valeur les travaux du cluster NExT MAD4AM dédié à la fabrication additive et, d’autre part, à échanger sur les problématiques interdisciplinaires qu’ils soulèvent, avec les autres participants régionaux et nationaux invités par le cluster.

Lien vers le site

 

Comité d'organisation

Comité scientifique

Éric Leroy (DR CNRS, Gepea)

Franck Halary (CR, CR2TI)

Benoit Furet (PR, LS2N)

Nordine Leklou (PR, GeM)

Alain Bernard (Professeur émérite ECN)

Sofiane Guessasma (DR,Inrae)

Pierre Weiss (PR, RMeS)

Elodie Paquet (MCF, LS2N)

Jean-Yves Hascoet (PR, GeM)

Frantz Rowe (PR, Lemna)

Paul Veron (MCF, DCS)

Raphaël Poryles (MCF, Gepea)

Pascal Paillard (PR, Polytech)

Maxime Mahé (CR, TENS)

Éric Leroy (DR CNRS, Gepea)

Franck Halary (CR, CR2TI)

Benoit Furet (PR, LS2N)

Nordine Leklou (PR, GeM)

Alain Bernard (Professeur émérite ECN)

Sofiane Guessasma (CR, HDR Inrae)

Pierre Weiss (PR, RMeS)

Elodie Paquet (MCF, LS2N)

Alain Le Bail (PR, Gepea, Oniris)

Antoine Le Duigou (PR, IRDL)

Florence Jacob (MCF, Lemna)

Frantz Rowe (PR, Lemna)

Jean-Yves Hascoet (PR, GeM, ECN)

Maxime Mahé (CR, TENS)

Pascal Paillard (PR, Polytech)

Paul Veron (MCF, DCS)

Raphael Poryles (MCF, Gepea, Oniris)

Sebastien Le Loch (MCF, LS2N)

Sofiane Belhabib (MCF, Gepea)

Steven Le Corre (PR, LTeN)

Yves Grohens (PR, IRDL).

Colloque «  Spotlight on Stem Cells - Modeling diseases with hiPS cells » le 11/06/2024  

Nous avons le plaisir de vous inviter au Colloque “Spotlight on Stem Cells” le mardi 11 Juin 2024, lors des Journées Scientifiques de Nantes Université, à la Cité des Congrès de Nantes. Cette année, le Colloque aura pour thématique "la modélisation de pathologies à l'aide de cellules souches pluripotentes induites (iPS)".

Lien vers le site

Comité Organisation

    Betty Gardie (Institut du thorax, UMR 1087)
    Claire Pecqueur (CRCI2NA)

Comité Scientifique

    Anne Camus (RMES, UMR 1229)
    Laurent David (PF IPSC, CR2TI)
    Nathalie Gaborit (Institut du thorax, UMR 1087)
    Betty Gardie (Institut du thorax, UMR 1087)
    Matthieu Giraud (ITUN)
    Maxime Mahé (UMR 1235)
    Claire Pecqueur (CRCI2NA)
    Vincent Guen (CRCI2NA)

RMeS in the spotlight


Business magasine de l'université

Article paru en avril dernier "RMeS répare les tissus Humains"

Lien vers l'article
Vidéo : la journée mondiale de la santé bucco-dentaire
Interview par télénantes le 20 mars de Gilles Amador Del Valle dans le cadre de la journée mondiale de la santé bucco-dentaire

Magasine pleine vie, janvier 2024

Article de Claire Vinatier sur les traitements de l'arthrose
https://pvsamplersla5.immanens.com/fr/pvPageH5B.asp?puc=003234&nu=452&pa=4#4



Magazine Inserm, janvier 2024

 

Bio-impression, vers des modèles créés de toutes pièces.

Article de Vianney Delplace et Baptiste charbonnier parus dans le N°59 du magazine de l'Inserm.

https://www.inserm.fr/magazine/inserm-le-magazine-n59/





Ma gazine Que Choisir décembre 2023

"Mal de dos, prévenir et soulager les douleurs", Interviews de Catherine le Visage et Jérôme Guicheux

Lien vers l'article

https://kiosque.quechoisir.org/magazine-pratique-quechoisir-138-decembre-2023/

























 

Announcements

OLYMPiC2024

The REJOINT team is pleased to announce the funding of the "Novel strategies for Osteoarthritis treatment based on innate LYMPhoid Cells modulation (OLYMPiC2024)" ANR/DFG PRCI project, coordinated by Marie-Astrid Boutet (StratOA group, RMeS) and Irene Mattiola (Institute of Microbiology, Infectious Diseases and Immunology, Charité Universitätsmedizin, Berlin, Germany).

The OLYMPiC2024 project aims to:
- Decipher the diversity and spatial distribution of innate lymphoid cells (ILC) in joint tissues at different stages of OA and the correlation with the clinical features of the patients.
- Investigate the contribution of ILC subsets to the pathophysiology of OA and evaluating therapeutic agents aimed at modulating ILC activation in OA models.
- Study the role of the microbiota-dependent regulation of ILC in relevant models of OA, to bring the proof of concept for a diet-based microbiota/ILC-modulating strategy in OA dog patients.


TARMac Project

The REJOINT team is delighted to announce the funding of the TARMac project in the framework of the “Equipe FRM 2023” (Medical Research Foundation Team 2023). The FRM Team-TARMac will be coordinated by Jerome Guicheux with Marie-Astrid Boutet as a co-coordinator.
Involving more than 15 collaborators from the Rejoint team, TARMac will also benefit from the expertise of the Pitzalis’ Lab (London, UK), Escriou’s lab (Paris, FR) as well as the Preclinical Research and Investigation Center (CRIP) at the Oniris Vet school (Nantes, FR).
Our team will receive a 3-years funding starting in 2024 and aiming at better understanding macrophages diversity in the synovial tissue to help accurately stratify osteoarthritis (OA) patients, and design novel and efficient RNA-based treatments with a personalized approach. TARMac is organized into 3 work packages (WP) as follow:
- WP1. Characterise the synovial MΦ heterogeneity and its association with the disease phenotype and severity to develop a stratification for OA patients.
- WP2. Validate an innovative drug delivery strategy that allows the sustained release of therapeutic RNAs to efficiently modulate MΦ pathogenesis in OA joints.
- WP3. Bring the proof of concept that modulating the activity of specific MΦ subsets in murine models of OA efficiently prevents disease progression and bring the proof of safety in dogs.
This project, which involves multiple technologies and covers a broad range of our team members’ expertise along with a strong collaborative network, possesses all the ingredients for advancing scientific research in OA with a huge potential to accelerate the translation of basic scientific observations into patients’ benefits.

ANR PEPR CARN


As part of France 2030's acceleration strategies, one action is dedicated to the funding of translational research through the Priority Research Programs and Equipment (PEPR). The REJOINT team is delighted to announce a PEPR funding within the Biotherapies and Bioproduction of Innovative Therapies (BBiT) program. UMR 7057-MSC (F. Gazeau) and UMR 1229-RMeS (J. Guicheux) will co-lead the CARN project (3.5 M€) dedicated to the development of biotherapies based on the local delivery of therapeutic RNA by functionalized hybrid extracellular vesicles (EVs) for joint diseases. This project will also involve the UMR 8612 (E. Fattal), UMR 5253 (M. Morille), UMS 55-ART ARNm (C. Pichon) and UMR 1183-IRMB (C. Jorgensen).

CARN is a 4 year-project with a kick-off official date August 31, 2023.

It is organized into 5 workpackages (WP) as follows :

-WP1. Identification and validation of therapeutic RNAs for knee and intervertebral disc osteoarthritis. Leaders Claire Vinatier & Danièle Noel
-WP2. High yield production of mesenchymal stromal cells-derived EVs and RNAs and per-production hybridization of EVs and RNA. Leaders: Chantal Pichon & Florence Gazeau
-WP3. Engineering, optimization and functionalization of hybrid EVs. Leaders: Elias Fattal & Marie Morille
-WP4. Efficacy evaluation of hybrid EVs in vitro and in the zebrafish model. Leaders: Farida Djouad & Jerome Guicheux
-WP5. Pre-clinical studies in small (mice) and large (sheep) animal models of knee and disc osteoarthritis. Leaders: Catherine Le Visage & Christian Jorgensen

By proposing functionalized hybrid EVs decorated with recognition elements and loaded with disease-modifying therapeutic RNAs, CARN will open new therapeutic opportunities for hybrid EVs in the treatment of chronic inflammatory joint diseases.


Fondation d’entreprise Grand Ouest – Prix encouragement recherche – Projet ANDROID2

The REGOS team of the INSERM U1229-RMeS laboratory is pleased to announce the recent award to Guillaume MABILLEAU (INSERM U1229, RMeS) from the Fondation d’entreprise Grand Ouest. This award will help to pursue the development of dual GIP/GLP-2 analogues for the prevention and treatment of bone fragility.

 


Fondation Arthritis - SPOTT project


The REJOINT team is pleased to announce the funding of the "SPatial multi-Omic profiling of synovial tissue to uncover novel Therapeutic Targets in osteoarthritis (SPOTT)" project, coordinated by Marie-Astrid Boutet (StratOA group).

The SPOTT project aims to:
(i) Analyse the spatial multi-omic profile of OA synovial tissue to refine patients’ stratification,
(ii) Validate the expression of identified cellular or molecular targets for the future development of innovative therapeutic strategies.
SPOTT is an emergent project, which implements for the first-time breakthrough conceptual and technological approaches and will facilitate the development of larger impactful projects in the context of OA and beyond with a huge potential to accelerate the translation of basic scientific observations into patients’ benefits.

 

ANR ANR PVNS


Pigmented villonodular synovitis (PVNS) is a rare joint disease characterized by a benign proliferative lesion arising from synovia that results in a secondary inflammatory joint response, pain, and destruction. The PVNS project, coordinated by Benoit Le Goff and Frédéric Blanchard (RMeS, T-Syno group) in collaboration with Fabienne Coury (INSERM UMR1033, Lyon) and Jérôme Avouac (INSERM U1016 Paris), has 3 main aims:
- To better understand PVNS pathophysiology using high throughput technologies in a cohort of PVNS patients and identify new therapeutic targets
- To set up an in vitro platform to better understand the crosstalk between cells and test new drugs and therapeutic targets on cells and tissues from PVNS patients
- To use and further develop original mouse models of PVNS to test drugs or new therapeutic targets, combined with a local delivery system, for treating PVNS patients

 

Funding of a new project by the Fondation de l'Avenir


The objective of this project, coordinated by Benoit Le Goff and Frédéric Blanchard (RMeS, T-Syno group), is to provide proof of principle that the local delivery of molecules interacting with the CSF1 pathway is feasible and effective in in vitro and in vivo models of Pigmented villonodular synovitis (PVNS). We will test a panel of therapeutic molecules on PVNS cells and explants in vitro and measure their impact on cell viability. The active molecules will then be studied in a mouse model of synovial tissue xenograft from patients with PVNS.

 

ANR TARGET-OA


The REJOINT team of the INSERM U1229-RMeS laboratory is pleased to announce the recent funding of the “TARGET-OA: targeting the chondrocyte-derived CXCL12/endothelial cell CXCR4 axis in osteoarthritis” collaborative research project by the 2023 ANR Call. The ARGET-OA project is coordinated by Xavier Houard (INSERM UMRs 938 Centre de Recherche Saint Antoine, Paris) in collaboration with Marie-Hélène Lafage-Proust (INSERM U1059 SAINBIOSE, St Etienne) and Claire Vinatier (INSERM U1229-RMeS, AGE-OA group). In the TARGET-OA project, we propose that the CXCL12 / CXCR4 axis has a crucial role in the dialogue between hypertrophic chondrocytes and endothelial cells in OA. Our objectives are to define the role of this axis in pathological communication between chondrocytes and endothelial cells and to demonstrate that its targeting has a clinical interest in the treatment of OA.

 

ANR ANR DISPHPE


The REJOINT team of the INSERM U1229-RMeS laboratory is pleased to announce the recent funding of the DISPHPE collaborative research project by the 2022 ANR Call on Translational Research in Health. In the DISPHPE project: “Comprehensive study of DISP1 gene variants to reach genotype-phenotype relationships of congenital anterior midline defects” coordinated by Valérie Dupé (IGDR, Rennes), Anne Camus (BIODIV Group, INSERM U1229, RMeS) will develop human induced pluripotent stem cells-based experimental models to investigate key molecular and functional aspects of developmental disorders arising during embryogenesis and related to the signaling role of the notochord.


 

L’exploration du rôle de la senescence cellulaire dans la maladie discale soutenue par la SFR

Dans le cadre de sa subvention aux projets individuels de recherche, la Société Française de Rhumatologie (SFR) a attribué une bourse [de 20000€] au projet « MoSCITO » porté par Romain GUIHO (La MOdulation de la Sénescence Cellulaire comme Innovation Thérapeutique dans la discOpathie dégénérative). En plus de faire progresser considérablement la caractérisation des cellules sénescentes dans le disque intervertébral, le projet MoSCITO a l'ambition de valider une nouvelle approche thérapeutique, ouvrant la voie à des progrès concrets et considérables dans la gestion clinique de la maladie discale.

 

A new collaborative project funded by the SFR: Characterization and new therapeutic options for pigmented villonodular synovitis (PVNS). It will be coordinated by Benoit Le Goff and Frédéric Blanchard in collaboration with Fabienne Coury (INSERM UMR1033, Lyon) and Jérôme Avouac (INSERM U1016 Paris). This project aims to 
- set up a multicentric biocollection of patients with PVNS; 
- explore the mechanisms leading to the development of synovitis (inflammation, genetic mutations, vascular compartment) using high-throughput technologies
- evaluate in vitro the biological activity of several drugs, in particular those targeting the CSF1 pathway, on tissues /cells from PVNS patients.

 

Bourse novartis DREAMER

Dr Christelle DARRIEUTORT-LAFFITE
Sujet de recherche : Etude de la cicatrisation d’un défect tendineux du supra-épineux chez la souris : analyse transcriptomique des populations cellulaires impliquées  

Description du projet :
Résumé : Bien que les tendinopathies représentent une problématique médicale fréquente, les options thérapeutiques restent peu nombreuses. Le tendon ayant une faible vascularisation et une faible cellularité, ses capacités naturelles de régénération/réparation sont faibles. Ce contexte, associé à nos connaissances limitées de la biologie des cellules du tendon et de la régulation de la ténogenèse, font du traitement des tendinopathies un réel challenge médical et scientifique. Des données récentes issues du Single-cell RNA-Sequencing démontrent la présence de populations de ténocytes hétérogènes au sein du tendon sain. Aucune donnée n’est disponible sur les changements au sein de ces populations cellulaires après une lésion tendineuse.
Objectifs : Etudier par Single-Cell RNA-Sequencing les populations cellulaires présentes au sein du tendon lors des différentes phases de la cicatrisation après une lésion partielle induite chirurgicalement au niveau du supra-épineux. Les échantillons seront recueillis à différents temps : en phase inflammatoire (J7), à la phase de prolifération (J21) et lors de la phase de remodelage (J42). Les échantillons seront également étudiés en histologie et immunohistochimie aux différents temps expérimentaux.


 

ANR
ANR NEMESIS

Low back pain (LBP) has been associated with intervertebral disc (IVD) degeneration. The recent identification of the microRNA (miR) role in IVD biology and degeneration allows considering miRs as new targets, but also as new potential therapeutic agents. The development of in vivo delivery systems, particularly miR-loaded nanocarriers, has thus been an area of active research. As a whole, the objectives of the NEMESIS project are (i) to set-up the formulation and characterization of miR-loaded nanocarriers, (ii) to implement potency assays and assess the interactions of miR-loaded nanocarriers with target cells in vitro and in an ex vivo whole IVD culture system and (iii) to establish the proof of concept of miR-loaded nanocarriers as a new therapeutic option in the management of DDD in an ovine preclinical model and in canine clinical trials. The NEMESIS project is based on an inter- and multi-disciplinary consortium composed of J. Clouet (scientific leader, RMeS lab), M. Fusellier (scientific co-leader, RMeS lab and ONIRIS) and Elise Lepeltier (scientific partner, MINT lab, Angers).
 

ATIP-Avenir SAMBA

Mandibular atrophy induced by the lack of a proper dentition is a major medical and socio-economic burden worldwide: the remaining bone volume is not sufficient to place dental implants to restore physiological functions. Although bone augmentation procedures exist, they are often heavy and complex, costly, and not deprived of risks (e.g., autologous bone graft). The ATIP-Avenir SAMBA program (INSERM/CNRS) will allow for the creation of a new group in RMeS Lab to tackle this issue, by developing among others 3D-printed patient specific biomimetic scaffolds for bone regeneration.

 

MiRbone By SFR

Age-related bone loss is a major medical and socio-economic problem worldwide. Many microRNAs are involved in bone homeostasis and may play a role in the development of osteoporosis. In the miRbone project funded by the SFR, Valérie Geoffroy and Frédéric Jehan (REGOS team) propose to dissect, using an "omic" approach, the mode of regulation of bone metabolism by one of these microRNAs, miR-199a2, whose significant effect in bone mass accrual has been demonstrated, with the aim of identifying new therapeutic targets to improve the management of bone loss in elderly patients.

 

ANR ANR-DYNAM-OA


Osteoarthritis (OA) has no cure to date. To identify new therapeutic targets and screen drugs, researchers need in vitro OA joint models that are biologically relevant and reproducible. Bioprinting-assisted OA modeling is a promising avenue of research, yet bioprinting tools are limited. With the DYNAM-OA project, Vianney Delplace (BIOMAX group) propose to develop a new ultra-modular bioprinting toolbox, including a universal bioink platform and a strategy to produce gradient constructs, and apply these tools for the design of the first generation of bioprinted OA joint models.

 

ANR ANR-COBIOSTEM


Traumatic brain injuries (TBI) are a critical public health and socio-economic problem throughout the world, with limited treatment options available. Cell transplantation offers a viable treatment strategy for patients with TBI, but transplanted neurons alone often rapidly die and fail to integrate brain tissue, leading to limited recovery. In the COBIOSTEM project, led by Afsaneh Gaillard (INSERM U1084 - LNEC), Vianney Delplace (BIOMAX group) will design a new generation of injectable hydrogels to improve the survival rate of transplanted cortical neurons, and enhance the long-term efficacy of cell transplantation to the brain.
 

International Research Project (IRP) Inserm (2022) GLYCODISC


The goal of the GLYCODISC projet is to consolidate a cooperating relationship between France (PI: Catherine LE VISAGE, Inserm) and Hong Kong (PI: Barbara CHAN, The University of Hong Kong (HKU)), in the field of regenerative medicine for intervertebral disc disease and low back pain.
The funding (75 000 euros, duration 5 years) aims to primarily contribute to mobility and organization of meetings. The ultimate outcome of the program is to lay the foundation for a large-scale international collaborative project with scientists from both countries.
 

ANR ANR SmartIEs (2022)


The REJOINT team of the INSERM U1229-RMeS laboratory is pleased to announce the recent funding of the SmartIEs proposal as an ANR collaborative research project.
SmartIEs will be coordinated by Sylvia COLLIEC-JOUAULT (IFREMER) and will be carried out in collaboration with Stéphane CUENOT (Institut des Matériaux) and Catherine Le Visage (INSERM U1229, RMeS). The SmartIEs project will explore a cell-free strategy through conception of a smart hydrogel scaffold highly efficient to recruit regenerative progenitor cells and to stimulate their differentiation into appropriate cell lineages able to regenerate both cartilage and subchondral bone.

Publications


Automatic grading of intervertebral disc degeneration in lumbar dog spines

Frank Niemeyer, Fabio Galbusera, Martijn Beukers, René Jonas, Youping Tao, Marion Fusellier, Marianna A. Tryfonidou,
Cornelia Neidlinger-Wilke, Annette Kienle, Hans-Joachim Wilke

http://dx.doi.org/10.1002/jsp2.1326

Abstract and more


Optimizing the physical properties of collagen/hyaluronan hydrogels by inhibition of polyionic complexes formation at pH close to the collagen isoelectric point

Stéphanie De Oliveira, Gregor Miklosic, Joëlle Veziers, Sébastien Grastilleur, Thibaud Coradin, Catherine Le Visage, Jérôme Guicheux, Matteo D'Este, Christophe Hélary

PMID: 37971365 DOI: 10.1039/d3sm01330h

Abstract and more




Development of a DNA damage-induced senescence model in osteoarthritic chondrocytes

Mélina Georget, Anaïs Defois, Romain Guiho, Nina Bon, Sophie Allain, Cécile Boyer, Boris Halgand, Denis Waast, Gaël Grimandi, Alban Fouasson-Chailloux, Jérôme Guicheux, Claire Vinatier

 PMID: 33227437 PMCID: PMC7925350 DOI: 10.1016/j.joca.2020.11.004

Abstract and more



Recommendations for intervertebral disc notochordal cell investigation: From isolation to characterization

Williams R.J., Laagland L.T., Bach F.C., Ward L., Chan W., Tam V., Medzikovic A., Basatvat S., Paillat L., Vedrenne N.,
Snuggs J.W., Poramba-Liyanage D.W., Hoyland J.A., Chan D., Camus A., Richardson S.M., Tryfonidou M.A., Le Maitre C.L. (2023). Recommendations for intervertebral disc notochordal cell investigation: From isolation to characterization. JOR Spine 1272:1-22. DOI: 10.1002/jsp2.1272.


Abstract and more





Osteoarthritic chondrocytes undergo a glycolysis-related metabolic switch upon exposure to IL-1b or TNF

Anais Defois , Nina Bon, Alexandre Charpentier , Melina Georget, Nicolas Gaigeard, Frederic Blanchard, Antoine Hamel, Denis Waast, Jean Armengaud, Ophelie Renoult, Claire Pecqueur, Yves Maugars, Marie-Astrid Boutet , Jerome Guicheux, Claire Vinatier

Cell Communication and signaling

Abstract and more




 

PPARβ/δ-Interfering Peptide Enhanced Mesenchymal Stromal Cell Immunoregulatory Properties

Gautier Tejedor,Prisca Boisguerin, Éric Vivès, Christian Jorgensen, Jérôme Guicheux, Claire Vinatier, Claire Gondeau, and Farida Djouad

Stem Cells International

Abstract and more




Transition from continuous to microglobular shaped peptide assemblies through a Liesegang-like enzyme-assisted mechanism.

Runser J-Y, Fneich F, Senger B, Weiss P, Jierry L,  Schaaf P

Journal of Colloid and Interface Science, 2022 Nov 22


Abstract and more



IL-34 deficiency impairs FOXP3+ Treg function in a model of autoimmune colitis and decreases immune tolerance homeostasis.

Freuchet A, Salama A, Bézie S, Tesson L, Rémy S, Humeau R, Règue H, Sérazin C, Flippe L, Peterson P, Vimond N, Usal C, Ménoret S, Heslan JM, Duteille F, Blanchard F, Giral M, Colonna M, Anegon I, Guillonneau C.
Clin Transl Med. 2022 Aug;12(8):e988. doi: 10.1002/ctm2.988.
Abstract and more






 

New members

























 

PhD defense & HDR

 

La soutenance d'HDR de Vianney Delplace aura lieu le aura lieu le vendredi 14 juin à 9h (Amphi A, bâtiment Bias 2).

Intitulé: le design macromoléculaire au service de l'ingénierie biomédicale

Mis à jour le 17 May 2024.
https://rmes.univ-nantes.fr/